MorphoSys has a proven track record of successful alliances including research, development and commercial agreements with numerous leading pharmaceutical and biotechnology companies. The partnering efforts of our highly experienced Business Development (BD) team have laid the groundwork for MorphoSys’ transformation from a technology provider to a fully integrated, commercial-stage biopharmaceutical company.
The value generated through MorphoSys’ partnerships is evident in our advancing clinical pipeline, products on the market like Tremfya® and Monjuvi® (tafasitamab-cxix), and further underscored by our recent funding partnership with Royalty Pharma, worth more than $2 billion.
Each therapeutic program and each partner is different, and MorphoSys’ BD team has the experience, passion and mindset to craft creative partnership structures and generate a win-win outcome for all of us – most importantly for the patients.